The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. OBJECTIVE: To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising. INTERVENTION: Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up. MAIN OUTCOME MEASURES: Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52. RESULTS: For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]). CONCLUSION: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Gonzales et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“The effects of varenicline on subjective abstinence symptoms were of a magnitude similar to those observed in clinical efficacy trials (4, 36).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“Individuals who relapsed derived less enjoyment from smoking while taking varenicline [241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Nearly one quarter (21–23%) of patients taking varenicline for a short period of time (12 weeks) maintained abstinence at 52 weeks of follow-up.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Gonzales and colleagues [241] found a similar decrease in negative affect, but also found a significant decrease in restlessness in patients taking varenicline.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“This represents a significant improvement over sustained-release bupropion (14–16%) and placebo (8–10%).”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Two large, randomized, placebo-controlled studies released in 2006 related the efficacy of varenicline to that of bupropion in aided smoking cessation [233, 241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“numerous studies have shown that varenicline, a Food and Drug Administration-approved drug widely used to help people quit smoking, potently acts as a partial agonist at ␣42* nAChRs”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Gonzales et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Cigarette Smoking Among Adults--United States, 2003
(2005) · JAMA · doi:10.1001/jama.294.2.172 · Cited by 1,520
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Chronic Obstructive Pulmonary Disease
Juvelekian, G. S., & Stoller, J. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00161-2 · Cited by 7
Jhanjee, S., Jain, R., Jain, V., Gupta, T., Mittal, S., Goelz, P. M., & Schnoll, R. A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1075092 · Cited by 7
Annemans, L., Marbaix, S., Nackaerts, K., & Bartsch, P. (2015) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2015.03.004 · Cited by 7
Smoking cessation in Asians: focus on varenicline
Xiao, D., Chu, S., & Wang, C. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s60785 · Cited by 7
Mayer, O., Seidlerová, J., Černá, V., Kučerová, A., Bruthans, J., Vágovičová, P., Vaněk, J., Timoracká, K., Wohlfahrt, P., Filipovský, J., et al. (2015) · Personalized Medicine · doi:10.2217/pme.15.16 · Cited by 7
Simmons, S. J., Gentile, T. A., Mo, L., Tran, F. H., Ma, S., & Muschamp, J. W. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.053 · Cited by 7
Stevens, E. R., Farrell, D., Jumkhawala, S. A., & Ladapo, J. A. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.06.013 · Cited by 7
Chopra, D., Shah, A., Vadhariya, A., & Painter, J. T. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.05.031 · Cited by 7
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity
Ebbert, J. O. (2009) · International Journal of COPD · doi:10.2147/copd.s6300 · Cited by 7
Cost–effectiveness of varenicline for smoking cessation
Keiding, H. (2009) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.19 · Cited by 7
Cheong, Y. S., & Ahn, S. H. (2010) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2010.31.5.355 · Cited by 7
Prevención cardiovascular y rehabilitación cardiaca
Zarzosa, C. D. P., Grima, A., Luengo-Pérez, E., & Mazón‐Ramos, P. (2007) · Revista Española de Cardiología · doi:10.1157/13099714 · Cited by 7
Emerging drugs in chronic obstructive pulmonary disease
Seifart, C., & Vogelmeier, C. F. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902798055 · Cited by 7
Efficacy of Varenicline for Smoking Cessation
Dervaux, A., Kanit, M., & Laqueille, X. (2006) · JAMA · doi:10.1001/jama.296.21.2555-a · Cited by 7
Smoking Cessation in Men and Women
Potter, A. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14081032 · Cited by 7
Rennard, S. I. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.014 · Cited by 7
Wen, Y., Wang, I.-T., Hu, Y.-T., Cheng, H., Cheng, K., Shiu, M., & Tsai, Y. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107091 · Cited by 6
Selbach, C., Siebel, C., Lilienthal, J., Grouven, U., Knelangen, M., Kastaun, S., & Kranz, P. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0223 · Cited by 6
Jain, R. K., & Laiteerapong, N. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0665-7 · Cited by 6
Chronic respiratory disease and tobacco consumption. Review
Gambaryan, M. G. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-17-144-152 · Cited by 6
Marakoğlu, K., Kargın, N. Ç., Uçar, R. M., & Kızmaz, M. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1342751 · Cited by 6
Kangiser, M. M., Dwoskin, L. P., Zheng, G., Crooks, P. A., & Stairs, D. J. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000340 · Cited by 6
Cui, Y., Engelmann, J. M., Xian, J. Z., Minnix, J. A., Lam, C. Y., Karam‐Hage, M., Cinciripini, P. M., & Robinson, J. D. (2017) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2017.12.001 · Cited by 7
Ock, M., Shin, J. S., & Ra, S. W. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s344757 · Cited by 6
Watson, W. H., Ritzenthaler, J. D., Torres-González, E., Arteel, G. E., & Roman, J. (2022) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14893 · Cited by 6
Smoking and asthma: never the twain should meet
Sands, M. F. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.08.011 · Cited by 6
Using Nicotine Replacement Therapy to Assist in Reducing Cigarette Consumption before Quitting
McRobbie, H. J., Whittaker, R., & Bullen, C. (2006) · Disease Management & Health Outcomes · doi:10.2165/00115677-200614060-00003 · Cited by 6
Advances in the prevention and treatment of lung cancer
Hodkinson, P. S., & Sethi, T. (2011) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2011.219 · Cited by 6
Smoking Cessation: It Is Never Too Late
Nilsson, P. M., & Fagerström, K. (2009) · Diabetes Care · doi:10.2337/dc09-s352 · Cited by 6
Cowan, C. M., Wink, J. S., & DeZee, K. J. (2012) · American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00243.x · Cited by 6
Rigotti, N. A., Pipe, A., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010) · Circulation · doi:10.1161/circulationaha.110.960856 · Cited by 6
Anderson, J. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-4927-2.00034-7 · Cited by 6
Gobarani, R. K., Abramson, M. J., Bonevski, B., Weeks, G. R., Dooley, M. J., Smith, B. J., Veale, A., Webb, A. R., Kirsa, S. W., Thomas, D., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038184 · Cited by 7
Zawertailo, L. A., Zhang, H., Rahmani, N., Rajji, T. K., & Selby, P. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277408 · Cited by 6
Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation†
Keating, G. M., & Lyseng-Williamson, K. A. (2010) · CNS Drugs · doi:10.2165/11204710-000000000-00000 · Cited by 6
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski, E., Jane, J. S., O’Brien, E. M., Edens, E. L., Arnaout, B., Kerfoot, K. E., Keegan, K. A., Weiner, J., Russo, M., & Petrakis, I. L. (2013) · Journal of Dual Diagnosis · doi:10.1080/15504263.2013.835163 · Cited by 6
Escota, G. V., & Önen, N. F. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10062471 · Cited by 6
Partial nicotinic acetylcholine (α4β2) agonists as promising new medications for smoking cessation
Budhiraja, S., & Singh, J. (2008) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.44150 · Cited by 6
Smoking Cessation Rate and Its Predictors among Heavy Smokers in a Smoking-Free Hospital in Taiwan
Lin, C.-J., Huang, W.-H., Hsu, C.-Y., Tjung, J.-J., & Chan, H.-L. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182412938 · Cited by 6
Whitley, H. P., & Moorman, K. L. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.10.1440 · Cited by 6
Effects of varenicline, nicotine or placebo on depressive symptoms in postmenopausal smokers
Avery, N., Kenny, R. A., Kleppinger, A., Brindisi, J., Litt, M. D., & Oncken, C. A. (2014) · American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12130.x · Cited by 6
African Americans and Peripheral Arterial Disease: A Review Article
Ghidei, W., & Collins, T. C. (2012) · ISRN Vascular Medicine · doi:10.5402/2012/165653 · Cited by 7
Smoking cessation therapy considerations for patients with chronic kidney disease.
Manley, H. J., & Stack, N. M. (2008) · PubMed · Cited by 6
Kotz, D., & van Schayck, O. C. P. (2011) · CHEST Journal · doi:10.1378/chest.10-2919 · Cited by 6
Moving Forward in Smoking Cessation: Issues for Psychiatric Nurses
Schroeder, S. A. (2009) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390308330843 · Cited by 6
He, Y., Chen, J., Zhao, L.-H., & Qu, S. (2025) · Tobacco Induced Diseases · doi:10.18332/tid/208449 · Cited by 5
Ahmady, A. E., Heydari, G., Masjedi, M. R., Leischow, S. J., Lando, H. A., Shadmehr, M., & Fadaizadeh, L. (2015) · International Journal of Preventive Medicine · doi:10.4103/2008-7802.162667 · Cited by 5
Acetylcholine and Depression: Scrutinizing Future Therapeutic Targets for Novel Drug Development
Pannu, A. S., & Goyal, R. K. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328311930240907133618 · Cited by 5
Pittenger, S. T., Zeplin, L. C., Dwoskin, L. P., & Bevins, R. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4067-y · Cited by 5
Smoking Cessation After Brain Damage Does Not Lead to Increased Depression
Tranel, D., McNutt, A., & Bechara, A. (2012) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e3182492a9c · Cited by 5
Electron impact mass spectral study of halogenated N ‐acetyl‐ and N ‐propionylcytisines
Przybył, A. K., & Nowakowska, Z. (2011) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4976 · Cited by 5
Varenicline-Induced Coronary Thrombosis
Kalaycı, A., Eren, A., Kocabay, G., Karabay, C. Y., Geçmen, Ç., & Kırma, C. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013508931 · Cited by 5
Winhusen, T. M., Theobald, J., & Lewis, D. F. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.02.008 · Cited by 5
Improvement of Smoking Abstinence Rates With Increased Varenicline Dosage
Karam‐Hage, M., Kypriotakis, G., Robinson, J. D., Green, C. E., Mann, G., Rabius, V. A., Wippold, R., Blalock, J. A., Mouhayar, E., Tayar, J. H., et al. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000829 · Cited by 5
Nomogram to predict successful smoking cessation in a Chinese outpatient population
Zhu, N., Lin, S., Cao, C., Xu, N., Yu, X., & Chen, X. (2020) · Tobacco Induced Diseases · doi:10.18332/tid/127736 · Cited by 5
Sex Differences in Chronic Obstructive Pulmonary Disease
Ferrera, M. C., & Han, M. L. K. (2021) · Physiology in health and disease · doi:10.1007/978-3-030-63549-7_7 · Cited by 5
Benarroch, E. E. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50012-3 · Cited by 7
Treatment Options in Smoking Cessation: What Place for Bupropion Sustained-Release?
McCarthy, D. E., Jorenby, D. E., Minami, H., & Yeh, V. M. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2044 · Cited by 5
Cigarette smoking and cardiovascular disease
Fish, J., & Bartholomew, J. R. (2007) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-007-0063-z · Cited by 5
Tabakabhängigkeit und Raucherentwöhnung im Alter
Wolter, D. K. (2009) · Zeitschrift für Gerontopsychologie & -psychiatrie · doi:10.1024/1011-6877.22.4.181 · Cited by 5
Smoking cessation: an economic analysis and review of varenicline
Faulkner, M. A. (2009) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s4223 · Cited by 5
Shimadu, S., Hamajima, N., Okada, Y., Oguri, T., Murohara, T., Ban, N., Sato, M., & Hasegawa, Y. (2016) · Europe PMC (PubMed Central) · doi:10.18999/nagjms.78.2.205 · Cited by 5
Haarmann, H., Gossler, A., Herrmann, P., Bonev, S., Nguyen, X. P., Hasenfuss, G. P., Andreas, S., & Raupach, T. (2016) · Tobacco Induced Diseases · doi:10.1186/s12971-016-0091-x · Cited by 5
Jimenez-Ruiz, C. A., Pascual-Lledó, J. F., Cicero-Guerrero, A. M., Cristóbal-Fernández, M. I., Mayayo-Ulibarri, M., & Villar-Laguna, C. (2017) · Pulmonology · doi:10.1016/j.rppnen.2017.10.008 · Cited by 5
Improved sleep as an adjunctive treatment for smoking cessation
Patterson, F., & Ashare, R. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815373-4.00022-8 · Cited by 5
Willette, B. K. A., Nangia, A., Howard, S., DiPalma, D. T., McMillan, C., Tharwani, S. D., Evans, J., Wells, C., Slade, S. K., Hall, B. J., et al. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172766 · Cited by 5
Fucito, L. M., Wu, R., O’Malley, S. S., Hanrahan, T. H., Ikomi, J. T., Muvvala, S. B., Carroll, K. M., & Gueorguieva, R. V. (2020) · The Journal of Smoking Cessation · doi:10.1017/jsc.2020.13 · Cited by 5
Varenicline: Smoking Cessation in Patients with Medical and Psychiatric Comorbidity
Tonstad, S., & Els, C. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s4012 · Cited by 5
Tratamiento actual del tabaquismo
Regalado-Piñeda, J., Lara-Rivas, G., Osio-Echánove, J., & Ramírez‐Venegas, A. (2007) · Salud Pública de México · doi:10.1590/s0036-36342007000800018 · Cited by 5
Liu, Y., Paige, M. A., Olson, T. T., Al‐Muhtasib, N., Xie, T., Hou, S., White, M. P., Cordova, A., Guo, J. L., Kellar, K. J., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.036 · Cited by 5
Tague, C., Richter, K. P., Cox, L. S., Keighley, J. D., Hutcheson, T. D., Fitzgerald, S., & Ellerbeck, E. F. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw138 · Cited by 5
The evolving role of medical therapy for chronic stable angina
Eid, F., & Boden, W. E. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0044-y · Cited by 5
Jiménez, S. M., Medina, J. T., & Jiménez-Ángeles, L. (2015) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-319-13117-7_111 · Cited by 4
Robinson, L., Didier, N. A., Thomas, R., Vena, A. A., & King, A. C. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001864 · Cited by 6
Kady, A., Grodin, E. N., & Ray, L. A. (2024) · Alcohol and Alcoholism · doi:10.1093/alcalc/agae044 · Cited by 4
Johnstone, S., Cooper, R. K., Wray, J. M., Tonkin, S., Knapp, K. S., Colder, C. R., Maguin, E., Mahoney, M. C., Tiffany, S. T., Brandon, T. H., et al. (2025) · Addiction · doi:10.1111/add.16772 · Cited by 4
Evaluation of smoking cessation drug use and outcomes in the Netherlands
Beest, F. J. A. P., Overbeek, J. A., Smulders, M., van Spiegel, P. I., Meerding, W. J., & Herings, R. M. C. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2010.551165 · Cited by 4
Tobacco and Aboriginal people in NSW
Ivers, R. G. (2008) · New South Wales Public Health Bulletin · doi:10.1071/nb07123 · Cited by 4
Takeuchi, T., Nakao, M., Shinozaki, Y., & Yano, E. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2010.505342 · Cited by 4
Ahmed, S., Reena, R., Hussain, N., Ahmed, R., Amin, S., Ahmed, S. I., & Washdave (2015) · International Journal of Emergency Mental Health and Human Resilience · doi:10.4172/1522-4821.1000135 · Cited by 4
Okoli, C. T. C., Wiggins, A. T., Fallin‐Bennett, A., & Rayens, M. K. (2017) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12408 · Cited by 4
Assessing combined effects of varenicline and N‐acetylcysteine on reducing nicotine seeking in rats
Nall, R. W., Beloate, L. N., Meyerink, M. E., Penaloza, T., Doolittle, J. D., Froeliger, B., Kalivas, P. W., & García‐Keller, C. (2022) · Addiction Biology · doi:10.1111/adb.13151 · Cited by 4
Seo, Y. B., Paek, Y., Lee, C. M., Lee, E. S., Kang, H. S., Kim, S. Y., Roh, S., Park, D. W., An, Y. S., & Jo, S. (2023) · Journal of the Korean Society for Research on Nicotine and Tobacco · doi:10.25055/jksrnt.2023.14.2.41 · Cited by 4
Vareniclin – medikamentöse Therapie der Tabakabhängigkeit
Tschabitscher, P., Homaier, I., Lichtenschopf, A., & Groman, E. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-008-0636-6 · Cited by 4
Hospitalization as a Teachable Moment for Cigarette Smoking Cessation
Son, K. Y. (2015) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2015.36.2.44 · Cited by 4
Shiltz, D. L., Paniagua, A., & Hastings, J. E. (2011) · The Journal of Smoking Cessation · doi:10.1375/jsc.6.1.65 · Cited by 4
Varenicline may reduce negative effect while aiding smoking cessation
Hays, J. T. (2013) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101435 · Cited by 4
Therapies for Smoking Cessation: A Meta-analysis of Double-blind Randomized Controlled Trials
Dabas, D. (2018) · Journal of Health Sciences & Research · doi:10.5005/jp-journals-10042-1069 · Cited by 4
Russo, C., Caponnetto, P., Cibella, F., Maglia, M. G., Alamo, A., Campagna, D., Frittitta, L., Mauro, M. D., Leotta, C., Mondati, E. G. M., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02684-1 · Cited by 4
Genetics of Substance Use Disorders
Arpana Agrawal, A., & Lynskey, M. T. (2014) · Springer eBooks · doi:10.1007/978-1-4614-9509-3_7 · Cited by 4
Batra, A., Mann, K. F., Berner, M. M., & Günthner, A. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-22485-0.00009-9 · Cited by 4
Pharmacological smoking cessation of adults aged 30–50 years with COPD
Andelius, D. K., Hilberg, O., Ibsen, R., & Løkke, A. (2022) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-022-00301-y · Cited by 4
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms
Zhang, H., Gilbert, E., Hussain, S., Veldhuizen, S., Foll, B. L., Selby, P. L., & Zawertailo, L. A. (2022) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntac288 · Cited by 5
Varenicline Should Be Used as a First-Line Treatment to Help Smokers With Mental Illness Quit
Williams, J. M. (2012) · Journal of Dual Diagnosis · doi:10.1080/15504263.2012.670848 · Cited by 4
Varenicline: A Novel Nicotinic Receptor Partial Agonist for Smoking Cessation
Kerr, J. L., Timpe, E. M., & Karpinski, J. P. (2007) · Journal of Pharmacy Technology · doi:10.1177/875512250702300105 · Cited by 4
Tolérance de la varénicline en pratique courante
Dupont, P., Gillet, C., Guérin, M., Kalamarides, S., Larinier, É., Meignan, C., Moreau, A., Guillaumin, C., & Perriot, J. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2009.07.016 · Cited by 4
Use of a liquid nicotine delivery product to promote smoking cessation
Geimer, N., Olson, C. E., Baumgarten, D., Kepner, J. L., & Mahoney, M. C. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-155 · Cited by 4
Smoking and Schizophrenia: Prevalence, Mechanisms and Implications for Treatment
Cather, C., Barr, R. S., & Evins, A. E. (2008) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.2.1.5 · Cited by 4
Pharmacologically, are smokers the same as non-smokers?
Bani, M., Andorn, A. C., & Heidbreder, C. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.11.003 · Cited by 5
Heath, J., Inglett, S., Young, S., Joshua, T. V., Sakievich, N., Hawkins, J., Andrews, J. O., & Tingen, M. S. (2012) · Nursing Clinics of North America · doi:10.1016/j.cnur.2011.10.005 · Cited by 4
Metadata
- Authors
- Gonzales, D.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gonzales, David
- ORCID
- Gonzales, David
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-05
- Volume
- 296
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107200746
- Cited by
- 1,361
- References
- 29
- Citations by year
- 2026: 32 · 2025: 21 · 2024: 25 · 2023: 25 · 2022: 34 · 2021: 26 · 2020: 52 · 2019: 49 · 2018: 41 · 2017: 51 · 2016: 50 · 2015: 70 · 2014: 74 · 2013: 80 · 2012: 94
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oregon Health and Science University
- Cardinal Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, bupropion sustained release, smoking cessation, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, continuous abstinence, exhaled carbon monoxide, brief counseling, nicotine replacement therapy, drug safety, adverse events, relapse, nicotine withdrawal symptoms, nicotine self-administration
- MeSH terms
- Varenicline, Adult, Benzazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
